Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Hims & Hers' weight loss business continues to be a major focus for the company, and that segment is on pace to bring in $725 million in revenue in 2025, Yemi Okupe, Hims & Hers' chief financial officer, said during the Q3 call with investors in early November
More affordable alternatives may be available and worth discussing with a healthcare provider
Retatrutide is an investigational triple incretin receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Semaglutide is the established standard of care with unmatched evidence breadth, proven cardiovascular benefit, and the flexibility of injectable and oral formulations
Last resort option
Tchang says
US$ 20.75
US$ 24.17
US$ 24.33
US$ 28.04
US$ 26.04
